Expertise in
40
conditions

Dr. Isaac Tafur

Hematology Oncology | Oncology
4101 22nd Place, 
Lubbock, TX 
Accepting New Patients
Expertise in
40
conditions
4101 22nd Place, 
Lubbock, TX 

Overview

Isaac Tafur is a Hematologist Oncology specialist and an Oncologist in Lubbock, Texas. Dr. Tafur is highly rated in 40 conditions, according to our data. His top areas of expertise are Inflammatory Breast Cancer, Lung Cancer, Paget Disease of the Breast, and Small Cell Lung Cancer (SCLC). Dr. Tafur is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology
Oncology

Licenses

Internal Medicine in NM

Hospital Affiliations

Nor-Lea Hospital District
Covenant Medical Center
Covenant Childrens Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Sky Community Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER COMMERCIAL
View 12 Less Insurance Carriers -

Locations

4101 22nd Place, Lubbock, TX 79410

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Ladiratuzumab Vedotin
Study Phase: Phase 2
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies
Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug
Study Drug: Fenretinide (4-HPR) plus Intravenous Safingol
Study Phase: Phase 1
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma
Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma
Enrollment Status: Terminated
Publish Date: August 27, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 15 Less Clinical Trials

1 Total Publications

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
Journal: Breast cancer research : BCR
Published: January 01, 2014
Similar Doctors
Expertise in
62
conditions
Dr. Donald P. Quick
Hematology Oncology | Oncology
Expertise in
62
conditions
Dr. Donald P. Quick
Hematology Oncology | Oncology
4101 22nd Place, 
Lubbock, TX 
 (0.1 miles away)
806-725-8000
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Donald Quick is a Hematologist Oncology specialist and an Oncologist in Lubbock, Texas. Dr. Quick has been practicing medicine for over 44 years is highly rated in 62 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Adult Immune Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Hemangioma Thrombocytopenia Syndrome, and Bone Marrow Aspiration. Dr. Quick is currently accepting new patients.

Expertise in
13
conditions
Dr. Thomas Hutson
Oncology
Expertise in
13
conditions
Dr. Thomas Hutson
Oncology

UMC Cancer Center

602 Indiana Ave, 
Lubbock, TX 
 (1.3 miles away)
806-775-8600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Hutson is an Oncologist in Lubbock, Texas. Dr. Hutson is highly rated in 13 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Clear Cell Sarcoma, Nephrectomy, and Orchiectomy.

Expertise in
42
conditions
Dr. Rodolfo E. Martinez
Oncology | Hematology Oncology
Expertise in
42
conditions
Dr. Rodolfo E. Martinez
Oncology | Hematology Oncology
4101 22nd Place, 
Lubbock, TX 
 (0.1 miles away)
806-725-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rodolfo Martinez is a Hematologist Oncology specialist and an Oncologist in Lubbock, Texas. Dr. Martinez is highly rated in 42 conditions, according to our data. His top areas of expertise are Inflammatory Breast Cancer, Paget Disease of the Breast, Breast Cancer, Angiosarcoma, and Bone Marrow Aspiration. Dr. Martinez is currently accepting new patients.

Frequently Asked Questions about Dr. Isaac Tafur

How do I make an appointment with Dr. Isaac Tafur?

You can book an appointment with Dr. Isaac Tafur by calling their office at 806-725-8000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Isaac Tafur a top-rated expert for Inflammatory Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Isaac Tafur is classified as an Distinguished expert for Inflammatory Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Isaac Tafur specialize in?

While Dr. Isaac Tafur is a Hematology Oncology, they have specific expertise in Inflammatory Breast Cancer, Lung Cancer, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Isaac Tafur participate in research or clinical trials?

Yes. Dr. Isaac Tafur has published 1 articles and abstracts on conditions like Inflammatory Breast Cancer. You can view a list of Dr. Isaac Tafur's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Isaac Tafur accept my insurance?

Dr. Isaac Tafur accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 806-725-8000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tafur's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 32 Advanced Conditions
    View All 109 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile